Evaxion A/S (EVAX) Competitors $2.40 -0.07 (-2.63%) Closing price 03:26 PM EasternExtended Trading$2.38 -0.02 (-0.83%) As of 04:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVAX vs. ACXP, NEUP, RLYB, ABP, TXMD, NERV, EYEN, ALVR, ATHA, and IBIOShould you be buying Evaxion A/S stock or one of its competitors? The main competitors of Evaxion A/S include Acurx Pharmaceuticals (ACXP), Neuphoria Therapeutics (NEUP), Rallybio (RLYB), Abpro (ABP), TherapeuticsMD (TXMD), Minerva Neurosciences (NERV), Eyenovia (EYEN), AlloVir (ALVR), Athira Pharma (ATHA), and iBio (IBIO). These companies are all part of the "pharmaceutical products" industry. Evaxion A/S vs. Its Competitors Acurx Pharmaceuticals Neuphoria Therapeutics Rallybio Abpro TherapeuticsMD Minerva Neurosciences Eyenovia AlloVir Athira Pharma iBio Evaxion A/S (NASDAQ:EVAX) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Is EVAX or ACXP more profitable? Acurx Pharmaceuticals has a net margin of 0.00% compared to Evaxion A/S's net margin of -316.03%. Acurx Pharmaceuticals' return on equity of -526.78% beat Evaxion A/S's return on equity.Company Net Margins Return on Equity Return on Assets Evaxion A/S-316.03% -532.72% -78.32% Acurx Pharmaceuticals N/A -526.78%-223.78% Do analysts recommend EVAX or ACXP? Evaxion A/S presently has a consensus target price of $10.00, suggesting a potential upside of 315.80%. Acurx Pharmaceuticals has a consensus target price of $8.00, suggesting a potential upside of 1,532.65%. Given Acurx Pharmaceuticals' higher probable upside, analysts clearly believe Acurx Pharmaceuticals is more favorable than Evaxion A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Acurx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of EVAX or ACXP? 11.0% of Evaxion A/S shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 41.6% of Evaxion A/S shares are held by company insiders. Comparatively, 26.0% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, EVAX or ACXP? Evaxion A/S has a beta of 0.12, suggesting that its share price is 88% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.23, suggesting that its share price is 223% less volatile than the S&P 500. Does the media prefer EVAX or ACXP? In the previous week, Evaxion A/S had 2 more articles in the media than Acurx Pharmaceuticals. MarketBeat recorded 4 mentions for Evaxion A/S and 2 mentions for Acurx Pharmaceuticals. Acurx Pharmaceuticals' average media sentiment score of 0.30 beat Evaxion A/S's score of 0.01 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evaxion A/S 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Acurx Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, EVAX or ACXP? Evaxion A/S has higher revenue and earnings than Acurx Pharmaceuticals. Evaxion A/S is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvaxion A/S$3.34M1.01-$10.57M-$1.16-2.07Acurx PharmaceuticalsN/AN/A-$14.10M-$0.70-0.70 SummaryEvaxion A/S and Acurx Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get Evaxion A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVAX vs. The Competition Export to ExcelMetricEvaxion A/SMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.46M$1.98B$5.54B$8.95BDividend YieldN/AN/A5.38%4.08%P/E Ratio-2.0733.7627.3820.03Price / Sales1.0115.98422.31120.16Price / CashN/A54.7436.6357.47Price / Book-2.048.708.085.67Net Income-$10.57M-$62.39M$3.16B$248.47M7 Day Performance-7.14%1.12%2.12%2.90%1 Month Performance-12.23%3.63%4.43%5.75%1 Year Performance-84.87%4.59%35.62%21.36% Evaxion A/S Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVAXEvaxion A/S2.8271 of 5 stars$2.41-2.6%$10.00+315.8%-83.0%$3.46M$3.34M-2.0760ACXPAcurx Pharmaceuticals2.6132 of 5 stars$0.60+9.5%$8.00+1,227.8%-77.5%$12.91MN/A-0.863News CoverageGap UpNEUPNeuphoria Therapeutics1.3717 of 5 stars$6.05-11.0%$21.00+247.1%N/A$12.78M$10K0.00N/AGap DownHigh Trading VolumeRLYBRallybio2.0162 of 5 stars$0.31+1.8%$10.00+3,106.2%-73.1%$12.76M$640K-0.2940ABPAbproN/A$0.24+13.1%$4.00+1,594.9%N/A$12.69M$180K0.0015News CoverageHigh Trading VolumeTXMDTherapeuticsMD0.8796 of 5 stars$1.11+1.8%N/A-31.3%$12.62M$1.76M0.00420NERVMinerva Neurosciences4.0826 of 5 stars$1.77flat$5.00+182.5%-44.6%$12.38MN/A2.169Gap DownEYENEyenovia1.0651 of 5 stars$5.48+30.2%$2.00-63.5%-73.3%$12.14M$60K-0.0940News CoverageHigh Trading VolumeALVRAlloVirN/A$2.40-6.6%N/A-84.7%$12.10MN/A-0.12110Gap UpHigh Trading VolumeATHAAthira Pharma2.9229 of 5 stars$0.30-2.3%$11.25+3,700.7%-88.1%$11.83MN/A-0.1440Gap DownIBIOiBio1.7083 of 5 stars$0.71-7.6%$4.30+503.6%-62.1%$11.77M$375K0.00100High Trading Volume Related Companies and Tools Related Companies Acurx Pharmaceuticals Competitors Neuphoria Therapeutics Competitors Rallybio Competitors Abpro Competitors TherapeuticsMD Competitors Minerva Neurosciences Competitors Eyenovia Competitors AlloVir Competitors Athira Pharma Competitors iBio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVAX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion A/S - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
